<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>Drug Ads on TV</title>
    <meta content="L25DRU$02" name="slug"/>
    <meta content="25" name="publication_day_of_month"/>
    <meta content="9" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Monday" name="publication_day_of_week"/>
    <meta content="Editorial Desk" name="dsk"/>
    <meta content="26" name="print_page_number"/>
    <meta content="A" name="print_section"/>
    <meta content="4" name="print_column"/>
    <meta content="Opinion" name="online_sections"/>
    <meta content="http://www.nytimes.com/2000/09/25/opinion/L25DRU.html" name="alternate_url"/>
    <docdata>
      <doc-id id-string="1233589"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="indexing_service" type="descriptor">Advertising</classifier>
        <classifier class="indexing_service" type="descriptor">Finances</classifier>
        <person class="indexing_service">Ellis, Phil</person>
        <classifier class="online_producer" type="types_of_material">Letter</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion/Letters</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Advertising and Marketing</classifier>
        <classifier class="online_producer" type="general_descriptor">Finances</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20000925T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9502E1DC1F3BF936A1575AC0A9669C8B63" item-length="145" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>Drug Ads on TV</hl1>
      </hedline>
      <abstract>
        <p>Phil Ellis letter on Sept 20 article holds doctors and patients may need more incentives to avoid heavily advertised drugs when less costly drugs would work as well</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>To the Editor:</p>
        <p>Re your Sept. 20 news article about the effects of prescription drug advertising: Unlike other advertised products, consumers cannot simply rush out and buy the drugs they see on TV -- they must get permission from their doctors first.</p>
      </block>
      <block class="full_text">
        <p>To the Editor:</p>
        <p>Re your Sept. 20 news article about the effects of prescription drug advertising: Unlike other advertised products, consumers cannot simply rush out and buy the drugs they see on TV -- they must get permission from their doctors first.</p>
        <p>If it is true that people are buying heavily advertised drugs even though ''less expensive drugs would work just as well,'' then the key considerations may be whether doctors and patients need more incentives to be cost-conscious or more oversight from their much-maligned H.M.O.'s.</p>
        <p>PHIL ELLIS  Arlington, Va., Sept. 20, 2000</p>
      </block>
    </body.content>
  </body>
</nitf>
